Generic Name and Formulations:
Guanfacine (as HCl) 1mg, 2mg; tabs.
Promius Pharma, LLC
Indications for TENEX:
Initially 1mg/day at bedtime. May increase to 2mg/day at bedtime; usual max 3mg/day.
Severe coronary insufficiency. Recent MI. Cerebrovascular disease. Chronic renal or hepatic failure. Avoid abrupt cessation. Elderly. Labor & delivery: not recommended for treating hypertension due to pregnancy toxemia. Pregnancy (Cat.B). Nursing mothers.
Additive sedation with alcohol, other CNS depressants. Caution with microsomal enzyme inducing drugs (eg, barbiturates, phenytoin) in renal impairment.
Central alpha-2 agonist.
Dry mouth, somnolence, dizziness, headache, impotence, asthenia, constipation, fatigue.
Tabs 1mg—100, 500; 2mg—100
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy